Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg

Mylan

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Valacyclovir Hydrochloride Tablets 1000 mg; Drug: Valtrex® Tablets 1000 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT00649974

VALA-0404

Details and patient eligibility

About

The objective of this study was to investigate the bioequivalence of Mylan's valacyclovir hydrochloride 1000 mg tablets to GlaxoSmithKline's Valtrex® 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fasting conditions.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy, adult subjects, 18 years and older
• able to swallow medication

Exclusion criteria

• institutionalized subjects
• history of any significant disease
• use of any prescription or OTC medications within 14 days of start of study
• received any investigational products within 30 days prior to start of study

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

1

Experimental group

Description:

Valacyclovir Hydrochloride Tablets 1000 mg

Treatment:

Drug: Valacyclovir Hydrochloride Tablets 1000 mg

2

Active Comparator group

Description:

Valtrex® Tablets 1000 mg

Treatment:

Drug: Valtrex® Tablets 1000 mg